iBio reports new preclinical data on obesity candidate IBIO-610 and amylin program
Extended non-human primate data on IBIO-610 and rodent amylin findings were presented or set for presentation at ObesityWeek, PEGS Europe and an amylin therapeutics summit.
SEC filing